|
US4647580A
(en)
|
1985-07-18 |
1987-03-03 |
Syntex (U.S.A.) Inc. |
Treatment of Alzheimer's disease
|
|
US5043345A
(en)
|
1989-02-22 |
1991-08-27 |
Novo Nordisk A/S |
Piperidine compounds and their preparation and use
|
|
US5852029A
(en)
|
1990-04-10 |
1998-12-22 |
Israel Institute For Biological Research |
Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity
|
|
US5480651A
(en)
|
1992-03-16 |
1996-01-02 |
Regents Of The University Of California |
Composition and method for treating nicotine craving in smoking cessation
|
|
FI960747A7
(fi)
*
|
1993-08-19 |
1996-04-17 |
Novo Nordisk As |
Antipsykoottinen menetelmä
|
|
US5744476A
(en)
|
1994-06-27 |
1998-04-28 |
Interneuron Pharmaceuticals, Inc. |
Dopamine D1 agonists for the treatment of dementia
|
|
KR19990081828A
(ko)
|
1996-01-19 |
1999-11-15 |
피터 로버트 라파엘 |
3 사이클 엔진
|
|
DE19612504C2
(de)
|
1996-03-29 |
2003-10-23 |
Boehringer Ingelheim Kg |
Neue Wirkstoffkompositionen
|
|
GB9612710D0
(en)
|
1996-06-18 |
1996-08-21 |
Pfizer Ltd |
Method of treatment
|
|
EP0821954A1
(en)
|
1996-08-01 |
1998-02-04 |
Eli Lilly And Company |
Method for treating mental retardation
|
|
DK0821955T3
(da)
|
1996-08-01 |
2002-03-18 |
Lilly Co Eli |
Anvendelse af 3-(4-heoxyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridin (xanomelin) til behandling af bipolar lidelse
|
|
EP0821956A1
(en)
|
1996-08-01 |
1998-02-04 |
Eli Lilly And Company |
Method for treating disruptive behavior disorders
|
|
EP0821958A3
(en)
|
1996-08-01 |
1998-07-08 |
Eli Lilly And Company |
Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine (xanomeline) for treating excessive aggression
|
|
EP0821959A3
(en)
|
1996-08-01 |
1998-09-16 |
Eli Lilly And Company |
Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine for treating nicotine withdrawal
|
|
EP0821957A3
(en)
|
1996-08-01 |
1998-04-22 |
Eli Lilly And Company |
Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine (xanomeline) for treating substance abuse
|
|
AU5716898A
(en)
|
1997-01-08 |
1998-08-03 |
Warner-Lambert Company |
Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease
|
|
US6093724A
(en)
|
1998-08-18 |
2000-07-25 |
Ucb, S.A. |
Muscarinic agonists and antagonists
|
|
PT1257277E
(pt)
|
2000-02-24 |
2005-09-30 |
Pharmacia & Upjohn Co Llc |
Novas combinacoes de farmacos
|
|
US7084126B1
(en)
|
2000-05-01 |
2006-08-01 |
Healthpartners Research Foundation |
Methods and compositions for enhancing cellular function through protection of tissue components
|
|
JP2004502655A
(ja)
|
2000-06-30 |
2004-01-29 |
イーライ・リリー・アンド・カンパニー |
精神病の処置のための組み合わせ療法
|
|
US20040058914A1
(en)
|
2000-12-22 |
2004-03-25 |
Takayuki Doi |
Combination drugs
|
|
US6862890B2
(en)
|
2001-01-30 |
2005-03-08 |
Board Of Regents, University Of Texas System |
Process for production of nanoparticles and microparticles by spray freezing into liquid
|
|
US20040023951A1
(en)
|
2001-06-18 |
2004-02-05 |
Bymaster Franklin Porter |
Combination therapy for treatment of psychoses
|
|
AU2002337815A1
(en)
|
2001-10-05 |
2003-04-22 |
Suwalee Chandrkrachang |
Active agents using liposome beads
|
|
US20040224012A1
(en)
|
2001-10-05 |
2004-11-11 |
Pichit Suvanprakorn |
Topical application and methods for administration of active agents using liposome macro-beads
|
|
NZ534012A
(en)
*
|
2002-01-25 |
2006-12-22 |
Theravance Inc |
Substituted phenylacetic acid ester compounds as short-acting sedative hypnotic agents for anesthesia and sedation
|
|
WO2004060347A2
(en)
|
2002-09-03 |
2004-07-22 |
Transform Pharmaceuticals, Inc. |
Pharmaceutical propylene glycol solvate compositions
|
|
US7790905B2
(en)
|
2002-02-15 |
2010-09-07 |
Mcneil-Ppc, Inc. |
Pharmaceutical propylene glycol solvate compositions
|
|
AU2003223093B2
(en)
|
2002-05-03 |
2010-02-04 |
Israel Institute For Biological Research |
Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor
|
|
US8216609B2
(en)
|
2002-08-05 |
2012-07-10 |
Torrent Pharmaceuticals Limited |
Modified release composition of highly soluble drugs
|
|
US20050085463A1
(en)
|
2003-01-23 |
2005-04-21 |
Weiner David M. |
Use of N-desmethylclozapine to treat human neuropsychiatric disease
|
|
US20050250767A1
(en)
|
2003-01-23 |
2005-11-10 |
Weiner David M |
Use of N-desmethylclozapine to treat human neuropsychiatric disease
|
|
GB0307860D0
(en)
|
2003-04-04 |
2003-05-14 |
Novartis Ag |
Organic compounds
|
|
ES2405404T3
(es)
*
|
2003-10-29 |
2013-05-31 |
Wyeth Llc |
Composiciones farmacéuticas de liberación sostenida que comprenden aplindore y sus derivados
|
|
DE602004030931D1
(https=)
|
2003-11-04 |
2011-02-17 |
Supernus Pharmaceuticals Inc |
|
|
US7763609B2
(en)
|
2003-12-15 |
2010-07-27 |
Schering Corporation |
Heterocyclic aspartyl protease inhibitors
|
|
PT1696931E
(pt)
|
2003-12-22 |
2009-06-12 |
Acadia Pharm Inc |
Análogos diaril[a,d]ciclo-hepteno substituídos com amino utilizados como agonistas muscarínicos e métodos de tratamento de perturbações neuropsiquiátricas
|
|
US9016221B2
(en)
|
2004-02-17 |
2015-04-28 |
University Of Florida Research Foundation, Inc. |
Surface topographies for non-toxic bioadhesion control
|
|
ES2257152B1
(es)
|
2004-05-31 |
2007-07-01 |
Laboratorios Almirall S.A. |
Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
|
|
EP1841460A2
(en)
|
2004-06-18 |
2007-10-10 |
Neurochem (International) Limited |
Therapeutic formulations for the treatment of beta-amyloid related diseases
|
|
GB0428170D0
(en)
|
2004-12-23 |
2005-01-26 |
Biopartners Ltd |
Mono and Combination Therapy
|
|
GB0428180D0
(en)
|
2004-12-23 |
2005-01-26 |
Biopartners Ltd |
Combination therapy
|
|
JP5731094B2
(ja)
|
2005-02-11 |
2015-06-10 |
スティーブン・ウィルスＳｔｅｐｈｅｎ ＷＩＬＬＳ |
アセチルコリンエステラーゼ阻害剤による微小血管系疾患の治療
|
|
JP4732769B2
(ja)
|
2005-03-04 |
2011-07-27 |
富士フイルム株式会社 |
内視鏡装置
|
|
TW200800959A
(en)
|
2005-06-10 |
2008-01-01 |
Wyeth Corp |
Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
|
|
KR20080025079A
(ko)
|
2005-06-14 |
2008-03-19 |
쉐링 코포레이션 |
아스파르틸 프로테아제 억제제
|
|
US7390816B2
(en)
*
|
2005-06-21 |
2008-06-24 |
Bridge Pharma, Inc. |
Methods for treating urinary incontinence in patients suffering from memory disorders
|
|
EP2275095A3
(en)
|
2005-08-26 |
2011-08-17 |
Braincells, Inc. |
Neurogenesis by muscarinic receptor modulation
|
|
EP1933833B8
(en)
|
2005-09-02 |
2011-09-14 |
Theravida, Inc. |
Therapy for the treatment of overactive bladder
|
|
US8158152B2
(en)
|
2005-11-18 |
2012-04-17 |
Scidose Llc |
Lyophilization process and products obtained thereby
|
|
GB0607946D0
(en)
|
2006-04-21 |
2006-05-31 |
Minster Res The Ltd |
Mono and combination therapy
|
|
GB0607952D0
(en)
|
2006-04-21 |
2006-05-31 |
Minster Res Ltd |
Novel treatment
|
|
GB0607949D0
(en)
|
2006-04-21 |
2006-05-31 |
Minster Res The Ltd |
Mono and combination therapy
|
|
TW200811105A
(en)
|
2006-04-25 |
2008-03-01 |
Theravance Inc |
Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
|
|
EA014915B1
(ru)
|
2006-05-04 |
2011-02-28 |
Солвей Фармасьютикалс Б.В. |
Мускариновые агонисты для лечения расстройств контроля над побуждениями
|
|
US7905852B2
(en)
|
2006-05-16 |
2011-03-15 |
Barbara Jennings-Spring |
Skin-contacting-adhesive free dressing
|
|
US8097633B2
(en)
|
2006-11-15 |
2012-01-17 |
Rich Steven A |
Uses for quaternary ammonium anticholinergic muscarinic receptor antagonists in patients being treated for cognitive impairment or acute delirium
|
|
WO2008076287A2
(en)
|
2006-12-13 |
2008-06-26 |
Tuel Stephen M |
Methods of making pharmaceutical components for customized drug products
|
|
GB0702416D0
(en)
|
2007-02-07 |
2007-03-21 |
Argenta Discovery Ltd |
New combination
|
|
GB0702385D0
(en)
|
2007-02-07 |
2007-03-21 |
Argenta Discovery Ltd |
New combination
|
|
GB0702456D0
(en)
|
2007-02-08 |
2007-03-21 |
Astrazeneca Ab |
New combination
|
|
GB0702457D0
(en)
|
2007-02-08 |
2007-03-21 |
Astrazeneca Ab |
New combination 666
|
|
GB0703999D0
(en)
|
2007-03-01 |
2007-04-11 |
Astrazeneca Ab |
New combination 667
|
|
AU2008233232A1
(en)
|
2007-03-29 |
2008-10-09 |
Merck Sharp & Dohme Corp. |
Combination therapy for the treatment-of lower urinary tract symptoms
|
|
CL2008001970A1
(es)
*
|
2007-07-03 |
2009-03-27 |
Synthon Bv |
Perla con un nucleo de celulosa microcristalina, un recubrimiento soluble en agua con un polimero vinil pirrolidina, una capa con tolterodina y un aglutinante, y una capa de liberacion controlada con un poliacrilato; proceso para prepararla; forma de dosificacion, util en trastornos urinarios como vejiga hiperactiva.
|
|
EP2197444A1
(en)
|
2007-09-12 |
2010-06-23 |
Glaxo Group Limited |
Novel combination of therapeutic agents
|
|
WO2009037503A2
(en)
|
2007-09-18 |
2009-03-26 |
Astrazeneca Ab |
New combination - 012 for the treatment of respiratory diseases
|
|
JP2010540454A
(ja)
|
2007-09-21 |
2010-12-24 |
アカディア ファーマシューティカルズ，インコーポレーテッド |
ピマバンセリンと他の薬剤との併用投与
|
|
CA2713128C
(en)
|
2008-01-25 |
2016-04-05 |
Gruenenthal Gmbh |
Pharmaceutical dosage form
|
|
AU2009229372C1
(en)
|
2008-03-27 |
2017-02-02 |
Chase Pharmaceuticals Corporation |
Use and composition for treating dementia
|
|
WO2009132239A2
(en)
|
2008-04-24 |
2009-10-29 |
Trustees Of Boston University |
A network biology approach for identifying targets for combination therapies
|
|
GB0822077D0
(en)
|
2008-12-03 |
2009-01-07 |
Minster Res Ltd |
Novel treatments
|
|
CA2754203A1
(en)
|
2009-03-05 |
2010-09-10 |
Mithridion, Inc. |
Compounds and compositions for cognition-enhancement, methods of making, and methods of treating
|
|
US10265311B2
(en)
*
|
2009-07-22 |
2019-04-23 |
PureTech Health LLC |
Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
|
|
PT3061821T
(pt)
|
2009-07-22 |
2019-09-05 |
PureTech Health LLC |
Composições para tratamento de distúrbios melhorados por ativação de recetores muscarínicos
|
|
JP2013516497A
(ja)
|
2010-01-11 |
2013-05-13 |
ミスリィディオン，インク． |
認知増強のための化合物と組成物、製造方法、および治療方法
|
|
SG174658A1
(en)
|
2010-04-01 |
2011-10-28 |
Theravida Inc |
Pharmaceutical formulations for the treatment of overactive bladder
|
|
WO2012033956A1
(en)
|
2010-09-08 |
2012-03-15 |
Mithridion, Inc. |
Cognition enhancing compounds and compositions, methods of making, and methods of treating
|
|
AU2012253669A1
(en)
*
|
2011-05-10 |
2013-11-28 |
Theravida, Inc. |
Combinations of trospium and salivary stimulants for the treatment of overactive bladder
|
|
CA2835293C
(en)
|
2011-06-08 |
2020-08-18 |
Sti Pharma, Llc |
Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration
|
|
US20130289019A1
(en)
|
2012-04-26 |
2013-10-31 |
Amazing Grace, Inc. |
Methods of treating behaviorial and/or mental disorders
|
|
BR112015004902A2
(pt)
|
2012-09-05 |
2017-07-04 |
Chase Pharmaceuticals Corp |
métodos e composição neutroprotetores anticolinérgicos
|
|
CA2978244A1
(en)
|
2015-03-06 |
2016-09-15 |
Thomas N. Chase |
Oxybutynin-xanomeline transdermal therapeutic system combinations
|
|
CA2978214A1
(en)
|
2015-03-06 |
2016-09-15 |
Chase Pharmaceuticals Corporation |
Peripheral-anticholinergic muscarinic agonist combination
|
|
US10307409B2
(en)
|
2015-03-06 |
2019-06-04 |
Chase Pharmaceuticals Corporation |
Muscarinic combinations and their use for combating hypocholinergic disorders of the central nervous system
|
|
JP6566254B2
(ja)
|
2015-08-21 |
2019-08-28 |
セイコープレシジョン株式会社 |
フォーカルプレーンシャッタおよび光学機器
|
|
PE20181295A1
(es)
*
|
2015-09-01 |
2018-08-07 |
First Wave Bio Inc |
Metodos y composiciones para tratar afecciones asociadas a una respuesta inflamatoria anomala
|
|
EP3347012A4
(en)
|
2015-09-11 |
2019-04-17 |
Chase Pharmaceuticals Corporation |
MUSCARIN COMBINATIONS AND THEIR USE FOR COMBATING HYPOCHOLINERGIC DISORDER OF THE CENTRAL NERVOUS SYSTEM
|
|
CL2018000559A1
(es)
|
2015-10-14 |
2018-08-17 |
First Wave Bio Inc |
Métodos y composiciones para tratar condiciones asociadas con respuestas inflamatorias anormales
|
|
CN108697688A
(zh)
|
2016-01-20 |
2018-10-23 |
塞拉维达公司 |
用于治疗多汗症的方法和组合物
|
|
WO2017147104A1
(en)
|
2016-02-24 |
2017-08-31 |
Chase Pharmaceuticals Corporation |
Muscarinic m2-antagonist combinations
|
|
WO2018212312A1
(ja)
|
2017-05-19 |
2018-11-22 |
武田薬品工業株式会社 |
スクリーニング方法
|
|
JP2021527708A
(ja)
|
2018-04-19 |
2021-10-14 |
ウジャル ヘルス ゲーエムベーハーＵｃａｒ Ｈｅａｌｔｈ Ｇｍｂｈ |
表面、空気、繊維、塗料、プラスチック、シリコーンおよび木材、ポリエチレン；金属および誘導体の抗菌性
|
|
KR102408292B1
(ko)
*
|
2018-09-28 |
2022-06-10 |
카루나 세러퓨틱스 인코포레이티드 |
무스카린성 수용체 활성화에 의해 개선된 장애의 치료를 위한 조성물 및 방법
|
|
CN120514706A
(zh)
|
2019-11-18 |
2025-08-22 |
卡鲁娜治疗学有限公司 |
用于治疗由毒蕈碱受体激活所缓解的障碍的组合物和方法
|
|
US20210145804A1
(en)
|
2019-11-18 |
2021-05-20 |
Karuna Therapeutics, Inc. |
Compositions and methods for treating disorders ameliorated by muscarinic receptor activation
|
|
JP2024507367A
(ja)
|
2021-02-24 |
2024-02-19 |
カルナ セラピューティックス，インコーポレイテッド |
ムスカリン受容体活性化によって改善される障害を処置するための方法
|
|
US20220370454A1
(en)
|
2021-05-18 |
2022-11-24 |
Karuna Therapeutics, Inc. |
Methods for treating central nervous system disorders with muscarinic receptor activation and antipsychotics
|
|
WO2023196952A2
(en)
|
2022-04-07 |
2023-10-12 |
Karuna Therapeutics, Inc. |
Methods for treating disorders ameliorated by muscarinic receptor activation
|